Compare Trevena, Inc. with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
USD 0 Million ()
NA (Loss Making)
NA
0.00%
-0.87
164.67%
-0.00
Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Sep 2024)
Net Profit:
-5 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-99.2%
0%
-99.2%
6 Months
-99.31%
0%
-99.31%
1 Year
-99.88%
0%
-99.88%
2 Years
-99.96%
0%
-99.96%
3 Years
-100.0%
0%
-100.0%
4 Years
-100.0%
0%
-100.0%
5 Years
-100.0%
0%
-100.0%
Trevena, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
5.71%
EBIT Growth (5y)
-4.55%
EBIT to Interest (avg)
-31.55
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.87
Sales to Capital Employed (avg)
0.05
Tax Ratio
0.24%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
15.89%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-0.04
EV to EBIT
-0.66
EV to EBITDA
-0.67
EV to Capital Employed
-6.86
EV to Sales
21.11
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
Bollinger Bands
Sideways
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot : Sep 2024
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 5 Schemes (1.34%)
Foreign Institutions
Held by 6 Foreign Institutions (0.15%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Sep'24 - QoQ
Sep'24
Jun'24
Change(%)
Net Sales
0.30
0.30
Operating Profit (PBDIT) excl Other Income
-5.50
-6.40
14.06%
Interest
0.00
0.50
-100.00%
Exceptional Items
0.40
1.80
-77.78%
Consolidate Net Profit
-4.90
-4.90
Operating Profit Margin (Excl OI)
-19,706.70%
-20,009.20%
30.25%
USD in Million.
Net Sales
QoQ Growth in quarter ended Sep 2024 is 0.00% vs 0.00% in Jun 2024
Consolidated Net Profit
QoQ Growth in quarter ended Sep 2024 is 0.00% vs 36.36% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'23
Dec'23
Dec'22
Change(%)
Net Sales
3.10
-0.40
875.00%
Operating Profit (PBDIT) excl Other Income
-34.40
-55.50
38.02%
Interest
3.60
1.30
176.92%
Exceptional Items
2.10
11.20
-81.25%
Consolidate Net Profit
-40.30
-53.70
24.95%
Operating Profit Margin (Excl OI)
-11,292.20%
0.00%
-1,129.22%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2023 is 875.00% vs -166.67% in Dec 2022
Consolidated Net Profit
YoY Growth in year ended Dec 2023 is 24.95% vs -4.07% in Dec 2022
About Trevena, Inc. 
Trevena, Inc.
Pharmaceuticals & Biotechnology
Trevena Inc. is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers. It is also developing TRV250, a G protein biased ligand targeting the o-receptor, as a compound with a non-narcotic mechanism for the treatment of migraine. TRV250 also may have utility in a range of other central nervous system (CNS) indications. It is focused on commencing a Phase I study of TRV250 in the United Kingdom. Its ABLE product platform is a collection of biological information, in vitro assays, know-how and expertise that it uses to identify unique G protein coupled receptors (GPCR)-targeted biased ligands with various pharmaceutical properties.
Company Coordinates 
Company Details
955 Chesterbrook Blvd Ste 110 , CHESTERBROOK PA : 19087-5627
Registrar Details






